Inventor · disambiguated record
James Barnaby Trager
Also filed as: TRAGER JAMES · TRAGER JAMES B · TRAGER JAMES BARNABY
9 granted patents·15 pending applications·45 citations·filing 2014–2025
86Inventor score
Files withNKARTA INC18NAT UNIV SINGAPORE3DENDREON CORP1DENDREON PHARMACEUTICALS INC1DENDREON PHARMACEUTICALS LLC1
Top patents by PatentIndex Score
24 records- 0194US11253547B2CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2020·Granted Feb 22, 2022·11 cites·19 claims
- 0294US11154575B2Cancer immunotherapy using CD19-directed chimeric antigen receptorsNKARTA INC·Filed 2020·Granted Oct 26, 2021·10 cites·25 claims
- 0394US11141436B2Immune cells engineered to express CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2020·Granted Oct 12, 2021·8 cites·16 claims
- 0492US11365236B2Truncated NKG2D chimeric receptors and uses thereof in natural killer cell immunotherapyNAT UNIV SINGAPORE·Filed 2018·Granted Jun 21, 2022·13 cites·6 claims
- 0589US12398187B2CD19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2022·Granted Aug 26, 2025·1 cites·24 claims
- 0688US12012458B2Genetically modified natural killer cells for CD70-directed cancer immunotherapyNKARTA INC·Filed 2021·Granted Jun 18, 2024·2 cites·26 claims
- 0775US2025296970A1Cd19-directed chimeric antigen receptors and uses thereof in immunotherapyNKARTA INC·Filed 2025·Application pending·0 cites
- 0873US12351617B2Immune cells comprising truncated NKG2D chimeric receptorsNAT UNIV SINGAPORE·Filed 2022·Granted Jul 8, 2025·0 cites·8 claims
- 0972US2025388645A1Immune Cells Comprising Truncated NKG2D Chimeric ReceptorsNAT UNIV SINGAPORE·Filed 2025·Application pending·0 cites
- 1071US2024360234A1Genetically modified natural killer cells for cd70-directed cancer immunotherapyNKARTA INC·Filed 2024·Application pending·0 cites
- 1163US2024358758A1Methods for treatment of autoimmune diseasesNKARTA INC·Filed 2024·Application pending·0 cites
- 1261US2025339528A1Selection of optimal cell donors and methods and compositions for enhanced expansion and cytotoxicity of donor cellsNKARTA INC·Filed 2022·Application pending·0 cites
- 1359US2023390392A1Multiplex gene edited cells for cd70-directed cancer immunotherapyNKARTA INC·Filed 2023·Application pending·0 cites
- 1457US2025319185A1Bcma-directed cellular immunotherapy compositions and methodsNKARTA INC·Filed 2022·Application pending·0 cites
- 1557US2021338727A1Natural killer cell compositions and immunotherapy methods for treating tumorsNKARTA INC·Filed 2019·Application pending·0 cites
- 1654US11970743B2Gene expression markers for predicting overall survival in subjects treated with sipuleucel-TDENDREON PHARMACEUTICALS LLC·Filed 2019·Granted Apr 30, 2024·0 cites·16 claims
- 1754US2025073266A1Dosing regimens for cancer immunotherapyNKARTA INC·Filed 2022·Application pending·0 cites
- 1854US2022411754A1Methods and compositions for enhanced expansion and cytotoxicity of natural killer cellsNKARTA INC·Filed 2020·Application pending·0 cites
- 1952US2024335536A1Methods of engineering immune cells for enhanced potency and persistence and uses of engineered cells in immunotherapyNKARTA INC·Filed 2021·Application pending·0 cites
- 2050US2023265390A1Enhanced expansion and cytotoxicity of engineered natural killer cells and uses thereofNKARTA INC·Filed 2021·Application pending·0 cites
- 2149US2023028399A1Bcma-directed cellular immunotherapy compositions and methodsNKARTA INC·Filed 2021·Application pending·0 cites
- 2248US10261091B2Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcomeDENDREON CORP·Filed 2014·Granted Apr 16, 2019·0 cites·11 claims
- 2346US2022233593A1Combinations of engineered natural killer cells and engineered t cells for immunotherapyNKARTA INC·Filed 2020·Application pending·0 cites
- 2442US2017107580A1Gene expression markers for predicting overall survival in subjects treated with sipuleucel-tDENDREON PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →